Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical OutcomesCatherine C. Coombs, Michael F. Berger, Ahmet Zehir et al.|Cell stem cell|2017Cited by 851
Cancer therapy shapes the fitness landscape of clonal hematopoiesisKelly L. Bolton, Dean F. Bajorin, Elsa Bernard et al.|Nature Genetics|2020Cited by 739
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, Nirav N. Shah et al.|The Lancet|2021Cited by 456
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R. Mato, Wojciech Jurczak, Jennifer A. Woyach et al.|New England Journal of Medicine|2023Cited by 213
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R. Mato, Colleen Dorsey, Lindsey E. Roeker et al.|Clinical Cancer Research|2020Cited by 115